These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 17962611

  • 1. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
    Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC, Chaudhary UB.
    Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
    [Abstract] [Full Text] [Related]

  • 2. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 3. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS, Kung EF, Petronic-Rosic V, Sethi A.
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [Abstract] [Full Text] [Related]

  • 4. The histologic spectrum of epithelial neoplasms induced by sorafenib.
    Kwon EJ, Kish LS, Jaworsky C.
    J Am Acad Dermatol; 2009 Sep; 61(3):522-7. PubMed ID: 19700018
    [Abstract] [Full Text] [Related]

  • 5. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P.
    Cutan Ocul Toxicol; 2009 Mar; 28(2):90-2. PubMed ID: 19514932
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Erythema multiforme induced by sorafenib.
    Feltes RA, Feito Rodríguez M, González-Beato MJ.
    Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
    [No Abstract] [Full Text] [Related]

  • 11. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
    Eng FC, Easson AM, Szentgyorgyi E, Knox JJ.
    Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
    Diamantis ML, Chon SY.
    J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183
    [Abstract] [Full Text] [Related]

  • 16. Localized dyskeratotic plaque with milia associated with sorafenib.
    Chappell JA, Burkemper NM, Semchyshyn N.
    J Drugs Dermatol; 2009 Jun; 8(6):573-6. PubMed ID: 19537383
    [Abstract] [Full Text] [Related]

  • 17. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT.
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.